Less Ads, More Data, More Tools Register for FREE

Pin to quick picksQuadrise Regulatory News (QED)

Share Price Information for Quadrise (QED)

Share Price is delayed by 15 minutes
Get Live Data
1.995    -0.215 (-9.73%)
Bid:
1.905
Ask:
2.19
Spread: 0.285 (14.961%)
Market Cap: £40.02m
QED Live PriceLast checked at - London Stock Exchange

Intraday Quadrise Share Chart

MAC2 Services Agreement

1 Apr 2025 07:00

RNS Number : 0192D
Quadrise PLC
01 April 2025
 

1 April 2025

Quadrise Plc ("Quadrise", "QED" or the "Company")

Signature of MAC2 Services Supply Agreement

Quadrise Plc (AIM: QED), the supplier of innovative energy solutions for a cleaner planet, is pleased to announce the signature of a Services Supply Agreement ("Agreement") with MAC2 Solutions NV ("MAC2") with regard to the production of MSAR® and bioMSAR™ fuels for the Company's forthcoming marine vessel trials on board the MSC Leandra V, expected to commence in Q2 2025 (the "Trials").

The Trials will comprise an initial Proof of Concept period using MSAR® and then bioMSAR™ for performance baseline tests, followed by 4,000 hours of operation (approximately 6-8 months) on bioMSAR™ in order to obtain a letter of no objection from engine manufacturer Wärtsilä upon success.

The Agreement sets out the responsibilities of Quadrise and MAC2 in respect of the Trials, which will be carried out following the installation and commissioning of Quadrise equipment at the MAC2 facility in Antwerp, Belgium in Q2 2025. MAC2 will be responsible for the supply of jetty space, utilities, permits and ad-hoc support services during the Trials, whilst Quadrise will be responsible for the provision of MSAR® and bioMSAR™ technology and fuel production equipment and personnel.

The remaining bilateral agreements to facilitate the Trials, including a toll manufacturing agreement between Cargill BV ("Cargill") and Quadrise in respect of fuel manufacture, continue to be advanced and further announcements will be made in due course.

Alongside the Trials, the parties plan to initiate commercial MSAR® and bioMSAR™ bunker supply operations to the marine sector through the MAC2 facilities in the Port of Antwerp-Bruges to MSC and other shipping companies on a permanent basis.

Commenting on the update, Jason Miles, Chief Executive Officer of Quadrise, said:

"We are pleased to have signed this services agreement with MAC2 to progress our plans for supplying MSAR® and bioMSAR™ to the marine sector from Antwerp-Bruges. We look forward to working with them as we prepare for the trials on the MSC Leandra V in Q2 2025 and to a successful longer-term partnership as we progress to commercial supply."

 

For additional information, please contact:

 

Quadrise Plc

+44 (0)20 7031 7321

Andy Morrison, Chairman

Jason Miles, Chief Executive Officer

Nominated Adviser

Cavendish Capital Markets Limited

+44 (0)20 7220 0500

Ben Jeynes

Katy Birkin

George Lawson

Joint Brokers

Shore Capital Stockbrokers Limited

 

 

+44 (0)20 7408 4090

Toby Gibbs(Corporate Advisory)

Fiona Conroy (Corporate Broking)

 

 

 

VSA Capital Limited

Andrew Raca (Corporate Finance)

Andrew Monk (Corporate Broking)

+44 (0)20 3005 5000

Public & Investor Relations

 

 

 

BLUE Communications Limited

Rhys Thomas

Sam Deacon

 

 

+44 (0) 7595 227750

+44 (0)7527 558846

 

About Quadrise

Quadrise is the supplier of MSAR® and bioMSAR™ emulsion technology, fuels and biofuels, providing innovative solutions to reduce energy costs and greenhouse gas emissions today for clients in the global power generation, shipping, industrial and refining industries.

Learn more at: www.quadrise.com

 

 

This announcement contains inside information for the purposes of Article 7 of the Market Abuse Regulation (EU) 596/2014 as it forms part of UK domestic law by virtue of the European Union (Withdrawal) Act 2018 ("MAR") and is disclosed in accordance with the Company's obligations under Article 17 of MAR.

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
AGRDFLFXEXLEBBX
Date   Source Headline
1st Aug 20247:00 amRNSValkor Project Update
10th Jul 20247:00 amRNSMarine Project Update
26th Jun 20247:00 amRNSExtended agreement with BTG Bioliquids for bioMSAR
29th May 20247:00 amRNSRepresentation Agreement Addendum & Warrants Grant
28th May 20247:00 amRNSOCP Commercial Framework Agreement
2nd May 20247:00 amRNSQuadrise-Vertoro JDA to sea-trial bioMSAR Zero
29th Apr 20247:00 amRNSMarine Project Update
19th Apr 20247:00 amRNSValkor Project Update
12th Apr 20244:58 pmRNSResults of Open Offer
22nd Mar 20243:10 pmRNSExtension of Open Offer Closing Date
20th Mar 20241:01 pmRNSInvestor Presentation
19th Mar 20247:00 amRNSPlacing Results, Open Offer & Posting of Circular
18th Mar 20244:55 pmRNSProposed Placing, Subscription and Open Offer
18th Mar 20244:53 pmRNSInterim Results
15th Feb 20247:00 amRNSAgreement with Euthenia & BTG Bioliquids
6th Feb 20247:00 amRNSMarine Project Update
6th Dec 20237:00 amRNSUpdate re bioMSARâ„¢ and bioMSARâ„¢ Zero Development
27th Nov 20235:46 pmRNSResult of AGM
27th Nov 20237:00 amRNSAGM Statement
22nd Nov 20237:00 amRNSMorocco Project Update
9th Nov 20237:00 amRNSPublication of 2023 Sustainability Report
31st Oct 202312:45 pmRNSMorocco Project Update
27th Oct 20234:20 pmRNSPosting of Annual Report & Notice of AGM
24th Oct 20239:33 amRNSChange of Nominated Adviser
2nd Oct 20237:30 amRNSDirectorate Change
2nd Oct 20237:00 amRNSFinal Results and Notice of AGM
12th Sep 20237:00 amRNSMorocco Project Update
29th Aug 20237:00 amRNSValkor Project Update
24th Aug 202312:29 pmRNSValkor Update
18th Aug 20233:46 pmRNSMorocco Update
4th Aug 20237:00 amRNSIssue of Share Options and Director/PDMR Dealing
1st Aug 20234:15 pmRNSDirector/PDMR Shareholding
28th Jul 20234:25 pmRNSDirector/PDMR Shareholding
25th Jul 20233:34 pmRNSResults of Open Offer
7th Jul 202312:00 pmRNSInvestor Presentation
7th Jul 202310:38 amRNSPlacing Results, Open Offer & Posting of Circular
7th Jul 20237:00 amRNSProposed Placing and Open Offer
22nd Jun 20237:00 amRNSMorocco Update
12th Jun 20237:00 amRNSValkor Site License & Supply Agreement
8th Jun 20237:00 amRNSJoint Development Agreement with BTG Bioliquids
26th May 20237:00 amRNSVertoro Joint Development Agreement Update
22nd May 20237:00 amRNSMorocco Update
16th May 20234:29 pmRNSReplacement: Business Update
16th May 20237:00 amRNSBusiness Update
25th Apr 20237:00 amRNSAppointment of Joint Broker
29th Mar 20237:00 amRNSInterim Results
28th Mar 20237:00 amRNSChange of Company Name
22nd Oct 20155:26 pmRNSDelisting of Quintain ordinary shares
15th Oct 20154:30 pmRNSHolding(s) in Company
15th Oct 20154:30 pmRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.